| | | | | | | | | Sponsored | | Access an evolving library of microorganisms for assay development and analytical studies. Select from available strains or work with our experts on custom growth to support feasibility, LOD, inclusivity, exclusivity, cross-reactivity, and other performance studies. Available in a variety of formats, including non-infectious viral lysates, live and heat inactivated culture fluids, purified DNA, and more. |
|
|
| | |
| |
| | |
|
|
| | | | | | Medical Laboratory Observer (MLO) is conducting a series of polls on point-of-care testing (POCT) in clinical laboratories. Tell us: What is the biggest POCT challenge your lab faces? |
|
|
|
| |
| | |
|
|
| | | | | | The Centers for Medicare & Medicaid Services (CMS) has revised the Clinical Laboratory Improvement Amendments of 1988 (CLIA) Post-Public Health Emergency (PHE) Guidance as of October 14, 2026. |
|
|
|
| |
| | |
|
|
| | | | | | Myasthenia gravis diagnosis relies on detecting specific autoantibodies, with recent advances like cell-based assays offering higher sensitivity, especially for seronegative cases, thus improving diagnostic accuracy and guiding therapy choices. |
|
|
|
| |
| | |
|
|
| | | | | | Sponsored | | Most of what determines how an assay performs is decided before you run your first qPCR reaction, sequence a sample, or build an immunoassay or flow cytometry panel. The Assay Development Handbook covers the pre-analytical decisions that get locked in early and how to make them before they're permanent. |
|
|
| | |
| |
| | |
|
|
| | | | | | Join Dr. William E. Winter on November 13 for a free CE webinar exploring the essential role of HbA1c in diagnosing and managing diabetes, including proper testing methodology, potential interferences, interpretation alongside CGM, and alternative glycemic measurements when HbA1c is unreliable. |
|
|
|
| |
| | |
|
|
| | | | | | For Cybersecurity Awareness Month, our sister publication, Healthcare Innovation (HCI), has published an article by David Raths describing the growing cybersecurity risks associated with agentic AI in healthcare, including concerns about patient data protection, accountability, and trust. |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|
